Overcoming the differentiation block in acute myeloid leukaemia [ 2017 - 2020 ]

Research Grant

Researchers: A/Pr Ross Dickins (Principal investigator)

Brief description Acute myeloid leukaemia (AML) is an aggressive leukaemia with poor overall survival. About 50% of AML cases have genetic mutations that disable PU.1, which in turn alters the expression of many other genes that cause leukaemia. We have developed new AML models allowing reversible inhibition of PU.1, and have shown that re-engaging PU.1 function causes AML regression. This project aims to understand PU.1 functions in AML and identify rational drug targets for treatment-resistant disease.

Funding Amount $AUD 831,869.40

Funding Scheme Project Grants

Notes Standard Project Grant